Sanjiv.Parant.Q4 FY25

Sanjiv.Parant. Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: 203P/E: 35.2Market Cap: ₹235 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

Margin guidance

No information is provided regarding the same in the latest conference call.

3 more insights locked — sign up free to unlock

Fundraise plans

No information is provided regarding the same in the latest conference call.

Order book

No information is provided regarding the same in the latest conference call.

Capex plans

No information is provided regarding the same in the latest conference call.

How does Sanjiv.Parant. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
1Sanjiv.Parant.

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sanjiv.Parant.?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio